CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale CEO and President sold 91,868 shares at $0.88 ($80,614)
- 4 Open-market sale SVP, Chief Legal Officer sold 13,034 shares at $0.88 ($11,437)
- 4 Open-market sale SVP, Chief Medical Officer sold 14,123 shares at $0.88 ($12,393)
- 4 Open-market sale SVP, Chief Operating Officer sold 20,412 shares at $0.88 ($17,912)
- 4 Open-market sale SVP, CFO and Treasurer sold 7,210 shares at $0.88 ($6,327)
- 8-K Event Material agreement
- 4 Open-market sale CEO and President sold 38,632 shares at $0.81 ($31,416)
- 4 Open-market sale SVP, Chief Medical Officer sold 7,539 shares at $0.81 ($6,131)
- 4 Open-market sale SVP, Chief Operating Officer sold 10,090 shares at $0.81 ($8,205)
- DEF 14A Proxy Proxy Statement
- 4 Open-market sale SVP, CFO and Treasurer sold 7,539 shares at $0.81 ($6,131)
- 4 Open-market sale SVP, Chief Legal Officer sold 6,677 shares at $0.81 ($5,430)
- 8-K Event Other events
- PRE 14A Proxy Proxy Statement (Preliminary)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Grant or award CEO and President acquired 293,125 shares (grant or award)
- 4 Grant or award SVP, CFO and Treasurer acquired 196,200 shares (grant or award)
Page 13 of 45 · 886 filings